Tirzepatide: difference between revisions
Diff·revision 14 → 15·17:50, 25 Dec 2024
Difference between revision 14 and revision 15 of Tirzepatide. 1 line changed; the page grew by 44 bytes.
| Revision 14 — 06:29, 6 Dec 2024 OrforglipronOona (talk) de-duplicate a repeated sentence 5,345 bytes +225 | Revision 15 — 17:50, 25 Dec 2024 StubSorterBot (talk) bot: add drug-class category 5,389 bytes +44 | ||
|---|---|---|---|
| 19 | }} | 19 | }} |
| 20 | {{hatnote|Not to be confused with [[Retatrutide]], which adds glucagon-receptor agonism. For the class, see [[Dual incretin agonist]].}} | 20 | {{hatnote|Not to be confused with [[Retatrutide]], which adds glucagon-receptor agonism. For the class, see [[Dual incretin agonist]].}} |
| + | 21 | {{medical|talk=Unapproved-compound notice}} | |
| 21 | 22 | ||
| 22 | '''Tirzepatide''' is a 39-residue synthetic peptide that activates both the receptor for [[Glucose-dependent insulinotropic polypeptide]] and the [[GLP-1 receptor]], making it the first [[Dual incretin agonist|dual incretin agonist]] to reach the market. Its backbone is derived from GIP rather than from GLP-1, and it is described in the literature as GIP-biased, with greater potency at the GIP receptor than at the GLP-1 receptor.{{r|coskun2018}} | 23 | '''Tirzepatide''' is a 39-residue synthetic peptide that activates both the receptor for [[Glucose-dependent insulinotropic polypeptide]] and the [[GLP-1 receptor]], making it the first [[Dual incretin agonist|dual incretin agonist]] to reach the market. Its backbone is derived from GIP rather than from GLP-1, and it is described in the literature as GIP-biased, with greater potency at the GIP receptor than at the GLP-1 receptor.{{r|coskun2018}} |